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Background: Lung immaturity due to preterm birth is a significant complication affecting neonatal health. Despite
the detrimental effects of supplemental oxygen on alveolar formation, it remains an important treatment for infants
with respiratory distress. Macrophages are traditionally associated with the propagation of inflammatory insults,
however increased appreciation of their diversity has revealed essential functions in development and regeneration.
Methods: Macrophage regulatory cytokine Colony-Stimulating Factor-1 (CSF-1) was investigated in a model of
neonatal hyperoxia exposure, with the aim of promoting macrophages associated with alveologenesis to protect/
rescue lung development and function. Neonatal mice were exposed to normoxia (21% oxygen) or hyperoxia (Hyp; 65%
oxygen); and administered CSF-1 (0.5 μg/g, daily × 5) or vehicle (PBS) in two treatment regimes; 1) after hyperoxia from
postnatal day (P)7-11, or 2) concurrently with five days of hyperoxia from P1-5. Lung structure, function and macrophages
were assessed using alveolar morphometry, barometric whole-body plethysmography and flow cytometry.
Results and discussion: Seven days of hyperoxia resulted in an 18% decrease in body weight and perturbation of lung
structure and function. In regime 1, growth restriction persisted in the Hyp + PBS and Hyp + CSF-1 groups, although
perturbations in respiratory function were resolved by P35. CSF-1 increased CSF-1R+/F4/80+ macrophage number by
34% at P11 compared to Hyp + PBS, but was not associated with growth or lung structural rescue. In regime 2, five days
of hyperoxia did not cause initial growth restriction in the Hyp + PBS and Hyp + CSF-1 groups, although body weight
was decreased at P35 with CSF-1. CSF-1 was not associated with increased macrophages, or with functional perturbation
in the adult. Overall, CSF-1 did not rescue the growth and lung defects associated with hyperoxia in this model; however,
an increase in CSF-1R+ macrophages was not associated with an exacerbation of lung injury. The trophic functions of
macrophages in lung development requires further elucidation in order to explore macrophage modulation as a strategy
for promoting lung maturation.Introduction
Immaturity of the lungs due to preterm birth is one of the
most significant complications affecting neonatal mortality.
As preterm infants with respiratory distress are born with
lungs at an anatomical stage not yet conducive to gas ex-
change, routine care practices include mechanical ventila-
tion and oxygen supplementation. However, these lifesaving
interventions can also cause permanent damage to the de-
veloping lung, resulting in a chronic lung disease termed* Correspondence: Sharon.Ricardo@monash.edu
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unless otherwise stated.bronchopulmonary dysplasia (BPD) [1,2]. Modern thera-
peutic improvements such as the administration of surfac-
tant and corticosteroids have seen a transformation in BPD
pathology away from the fibrotic injury of the past. Instead
today, with many extremely preterm babies now surviving,
‘new’ BPD pathology is characterised by a disruption of al-
veolar formation [3,4].
Delivery of high concentrations of oxygen to neonatal
animals is widely used to investigate the basis of arrested
alveolar development associated with BPD in preterm
infants [5,6]. In humans, alveolarisation begins in utero
at around 36 weeks gestation, with 85% of alveoli formed
after birth [7]. In the mouse, alveolar formation occurstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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birth and proceeding until P36 [8]. Exposure of the de-
veloping lung to high levels of oxygen results in inflam-
mation and oxidant damage, and dysregulation of
alveolar development [9-11]. Understanding the mecha-
nisms of alveolar formation has clinical relevance for the
development of therapeutic strategies to improve lung
maturation in preterm infants.
Macrophages are key immune cells commonly associ-
ated with inflammation and the propagation of tissue
injury associated with oxygen toxicity in hyperoxia ex-
posure. However, a greater appreciation of macrophage
diversity is revealing that this heterogenous cell type is
also essential in regulating organ development and re-
generation [12–15]. In particular, diversity in macro-
phage subpopulation activation in the lung has been
shown to be important in both the induction and reso-
lution of lung injury [16].
Colony-Stimulating Factor-1 (CSF-1) is a key regulator
of macrophage differentiation, proliferation, survival and
activation, and acts as a pleiotropic growth factor essen-
tial in reproduction and organogenesis [17]. During
pregnancy, uterine production of CSF-1 increases 1000-
fold [18], and macrophages colonise the embryo and are
present in large numbers in virtually all developing organs
[19]. The absence of CSF-1 results in severe developmen-
tal impairment including reduced growth, neurological
and reproductive defects, as well as altered development
of the mammary gland, bone and pancreas [20-22]. We
have previously reported that lung CSF-1R+ macrophages
increase during normal lung development and peak dur-
ing the alveolarisation stage [23]. In the absence of CSF-1,
alveolar macrophage populations are severely depleted
during postnatal development [24–26], and in adulthood
mice develop spontaneous emphysema associated with
deregulated matrix metalloproteinases (MMPs) and ab-
normal elastin deposition [26].
CSF-1 administration has been shown to enhance or-
ganogenesis. Increased branching morphogenesis was
observed in embryonic kidney explants following the
addition of CSF-1 [27], and in embryonic pancreas ex-
plants β-cell proliferation and insulin production were
increased [28]. Furthermore, CSF-1 is suggested to
preferentially regulate macrophage populations associ-
ated with trophic functions such as development [29].
While abnormalities seen in CSF-1-deficient animals
are associated with a virtual absence of tissue macro-
phages, organogenic enhancement with CSF-1 admin-
istration is correlated with increased macrophage
numbers [20-22,27,28].
CSF-1-responsive macrophages in developing embryonic
kidneys and lungs exhibit a gene expression profile charac-
teristic of an M2 or tissue remodelling-type macrophage
[27]. Similarly we have demonstrated the importance oftrophic macrophages in alveolarisation, with an upregula-
tion of M2 genes observed during this developmental stage
in the mouse [23]. Furthermore, CSF-1 has important im-
munomodulatory properties, and in a murine model of
neonatal hyperoxia, mesenchymal stem cell (MSC)-medi-
ated amelioration of injury was associated with increased
CSF-1 levels [30]. We hypothesise that the administration
of CSF-1 to promote augmentation of developmental mac-
rophages associated with alveolarisation may reduce the
need for damaging long-term oxygen therapy in preterm
newborns and attenuate the developmental arrest of the
lung associated with BPD.
The aim of this study was to determine the impact of
CSF-1 administration on lung maturation in a model of
hyperoxia-associated lung developmental perturbation,
when delivered either as a treatment after hyperoxia or
when administered prophylactically with concurrent
hyperoxia exposure. In particular, we assessed lung func-
tional maturation and the impact of a CSF-1-mediated
increase in macrophages. We found that CSF-1 did not
rescue the growth and pulmonary defects associated
with hyperoxia in this model; however the concomitant
increased infiltration of CSF-1-responsive macrophages
was not associated with exacerbation of lung injury.
Methods
Hyperoxia exposure
All animal experiments were approved by the Monash Uni-
versity Animal Ethics Committee and conducted in accord-
ance with the “Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes”. This study utilised
csf1r-EGFP mice, which express enhanced green fluores-
cent protein (EGFP) in cells of the myeloid lineage via the
insertion of an EGFP transgene under the control of the
Csf1r promoter [31]. Pregnant csf1r-EGFP mice were
allowed to litter-down naturally in individually ventilated
cages (Green Line IVC Sealsafe; Techniplast, Buguggiate,
Italy). Litters were randomly assigned to receive either nor-
moxia (ambient room air; 21% oxygen) or hyperoxia (65%
oxygen). Hyperoxia was achieved by mixing 100% medical
grade oxygen and medical grade dry air, delivered to cages
via Perspex(R) tubing into ventilation ports. Oxygen and car-
bon dioxide concentrations were continuously monitored by
a gas analyser (Servoflex MiniMP 5200, Servomex, Valley
Point, Singapore). Dams remained with their own pups for
the entire experiment. Boxes were briefly disconnected from
hyperoxia gases for a maximum of 15 minutes when injec-
tions were performed. Following hyperoxia exposure (regime
1: 7 days; regime 2: 5 days), mice were maintained in room
air until experimental endpoints at P11 and P35.
CSF-1 administration
Hyperoxia-exposed littermate pups received either mouse
recombinant CSF-1 (0.5 μg/g body weight; University of
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hicle (PBS), administered via intraperitoneal (i.p.) injection
at a final volume of 25 μl. Biological activity was confirmed
with in vitro culture assays demonstrating CSF-1-mediated
proliferation of bone-marrow derived macrophages (data
not shown). In treatment regime 1, neonatal pups were
continuously exposed to hyperoxia from birth for 7 days
with subsequent injections performed once daily for 5 days
from P7-11. In treatment regime 2, newborn pups were
exposed to hyperoxia and were administered CSF-1 con-
currently, and therefore a shorter exposure of 5 days was
used to facilitate 5 concurrent daily injections. At ex-
perimental endpoints (regime 1: P11 and P35; regime 2:
P5 and P35) mice were humanely euthanised via cer-
vical dislocation for morphometric or flow cytometric
analysis.
Plethysmography
Respiratory function was assessed using unrestrained
barometric whole-body plethysmography, as described
previously [23,32,33]. In brief, mice were placed in a
sealed cylindrical Perspex chamber (Neonate; 75 mm×
50 mm, Adolescent/Adult; 150 mm × 50 mm), and
changes in pressure caused by tidal breathing move-
ments were measured using a volumetric pressure trans-
ducer (model PT5A; Grass Instrument Co., Quincy,
MA, USA) and amplified (Octal Bridge Amp model
ML228 and Powerlab 8/30 model ML870; ADInstru-
ments, Bella Vista, NSW, Australia). Pressure fluctua-
tions were recorded using Chart™ software (v5.1;
ADInstruments). At the beginning of each session the
plethysmograph was calibrated by measuring the pres-
sure deflection caused by the injection of a known vol-
ume (300 μl) of air into the chamber. The temperature
and relative humidity within the chamber were noted at
the beginning and end of recordings (model HM34; Vai-
sala, Hawthorn, VIC, Australia). Waveform analysis
(Chart™; ADInstruments) was used to derive breath fre-
quency (breaths/min), total breath cycle time (ms), in-
spiration time (ms), expiration time (ms), tidal volume
(μL), minute volume (mL/min), inspiratory duty cycle
(%) and inspiratory flow rate (μL/sec). Measurements
were performed at P5 or P7 at the end of hyperoxia, fol-
lowing CSF-1 administration at P11 and then at P14,
P21, P28 and P35.
Morphometry
For morphometric assessments, the trachea was cannu-
lated immediately after euthanasia and the lungs
inflation-fixed in situ via intratracheal instillation of 10%
buffered formalin at a pressure of 20 cmH20. The entire
thorax was subsequently immersion fixed for 24 hr be-
fore lungs were dissected. The left lobe was processed,
embedded in paraffin wax, sectioned at 5 μm, mountedon Polysine™ slides (Menzel-Glaser, Braunschweig,
Germany) and stained with haematoxylin and eosin. Im-
ages from 15 non-overlapping fields of view were cap-
tured at × 400 magnification and ImagePro Plus software
(Media Cybernetics, Bethesda, MA, USA) was used to
assess mean linear intercept (MLI), as an estimate of al-
veolar diameter, and tissue/airspace percentage, as de-
scribed previously [34]. In brief, MLI was calculated by
superimposing two transverse lines over lung images
and counting intersecting points. The percentage air-
space and tissue was estimated by superimposing 21
equidistant line segments over lung images and counting
line termini intersections with either tissue or airspace,
respectively. Fields of view containing parenchyma only
were analysed, with care taken to exclude areas with air-
ways or extensive vasculature. Measurements were con-
ducted in a blinded manner by the same individual
(CVJ) to reduce bias.
Flow cytometry
To assess macrophage populations in hyperoxic lungs
and their response to CSF-1 treatment, whole lungs of
littermate mice underwent flow cytometric analysis at the
end of treatment at P11 or P5, with the final injection be-
ing administered 3 hours before lungs were collected.
Whole lungs underwent enzymatic and mechanical diges-
tion to yield a single cell suspension as described previ-
ously [12]. Red blood cells were lysed and cell suspensions
were filtered through a 40 μm cell strainer (BD Biosci-
ences, North Ryde, NSW, Australia). Cell counts were per-
formed using a Coulter® Particle Count and Size Analyzer
(Beckman Coulter Australia Pty Ltd, Gladesville, NSW,
Australia). 3 × 106 cells were immunolabelled with anti-
CD45 APC Cy7-conjugated (1:800; BioLegend, San Diego,
CA, USA; Clone 30-F11) and anti-F4/80 APC-conjugated
(1:200; eBioscience, San Diego, CA, USA; Clone BM8)
antibodies. Samples were run on a BD FACSCanto II
cytometer (BD Biosciences) and data analysis was per-
formed using FlowJo FCS analysis software (Tree Star
Inc., Ashland, OR, USA).
Statistical analysis
This study included 17 litters of mice, ranging between 4
and 8 pups per litter. The N numbers for bodyweight
and lung function analysis outlined in appropriate figure
legends are a cumulative of a minimum two repeated ex-
periments. Flow cytometric analysis was performed on
one representative litter for inter-litter comparison. Data
are presented as mean ± standard error of the mean
(SEM). Graphing and statistical analyses were performed
using GraphPad Prism™ (GraphPad Software; Section
3.14). Specific statistical tests used are outlined in figure
legends. A p value of less than 0.05 was considered sta-
tistically significant.
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Neonatal hyperoxia exposure for 7 days results in
decreased body weight and perturbations in lung
structure and function
Neonatal murine hyperoxia is a model of impaired alveolo-
genesis and a clinically relevant model of preterm lung
damage. In our hyperoxia model, neonatal mice were ex-
posed to 65% oxygen from birth for 7 days. Hyperoxia sig-
nificantly decreased growth of neonatal mice. At birth thereFigure 1 Neonatal hyperoxia exposure resulted in decreased growth
mice exposed to hyperoxia for 7 days from birth compared to neonates ex
estimation of mean linear intercept (B), percentage tissue (C) and percenta
lungs/treatment. Data were analysed using two-tailed unpaired t-tests. *p < 0
the decrease in tissue percentage and increase in alveolar size due to hypero
(H) display abnormal breath patterns compared to normoxic mice (G).was no significant difference in body weight between
groups (p = 0.09); however after 7 days of hyperoxia expos-
ure body weight was decreased by 18% compared to
normoxia-exposed offspring (4.37 ± 0.12 g vs. 3.57 ± 0.01 g,
p < 0.001; Figure 1A). Lung structural alterations were
assessed via morphometric analyses. Compared to nor-
moxia, hyperoxia resulted in a 17% increase in MLI (80.9 ±
2.1 μm vs. 94.6 ± 2.4 μm, p < 0.05; Figure 1B), a 6% decrease
in percentage tissue (44.3 ± 0.5% vs. 38.6 ± 1.1%, p < 0.05;and lung structural and functional alterations. Body weights of
posed to normoxia (A). n = 9 & 13 mice/treatment. Morphometric
ge airspace (D) in lungs exposed to hyperoxia and normoxia. n = 4 & 5
.05. Normoxia (E) and hyperoxia-exposed (F) lungs at P7 demonstrated
xia. Respiratory trace recordings revealed that mice exposed to hyperoxia
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airspace (55.7 ± 0.5% vs. 61.4 ± 1.1%, p < 0.05; Figure 1D).
These quantitative measurements reflect the histological
changes observed in hyperoxic lungs, where alveoli ap-
peared larger and secondary septation appeared to be im-
paired (Figure 1F), in comparison to the lungs of normoxic
mice which had smaller alveoli and evidence of extensive
secondary septation (Figure 1E). These structural perturba-
tions associated with hyperoxia exposure were reflected in
functional alterations (Table 1). Unrestrained barometric
whole-body plethysmography assessment of respiratory
function after 7 days of hyperoxia indicated that these mice
exhibited abnormal breathing patterns compared to nor-
moxic mice (Figure 1G&H). Quantification revealed signifi-
cant reductions in tidal volume (21% p < 0.0001), minute
volume (29% p < 0.01), breath frequency (9% p < 0.05) and
inspiratory flow rate (30% p < 0.001; Table 1). Functional al-
terations also included significant increases in total cycle
time (9% p < 0.05), expiration time (50% p < 0.001) and a
trend towards increased inspiration time (14% p = 0.08).
CSF-1 treatment after hyperoxia did not rescue body
weight, but increased macrophage numbers were not
associated with exacerbation of lung structural or
functional perturbation
In the first treatment regime, CSF-1 was administered
after 7 days of hyperoxia-induced lung injury to assess the
ability of CSF-1 therapy to rescue growth and promote al-
veolar development. Comparing hyperoxia and normoxia
groups, a significant reduction in body weight was ob-
served in Hyp + PBS mice, which persisted from P11
(6.43 ± 0.34 g vs. 5.07 ± 0.13 g, p < 0.001) to adulthood at
P35 (21.17 ± 0.47 g vs. 17.70 ± 0.76 g, p < 0.001; Figure 2A).
While both groups exposed to hyperoxia weighed signifi-
cantly less than the Norm group, there was no significantTable 1 Effect of neonatal hyperoxia exposure on lung functi
Normoxia
Tidal volume (μl) 13.64 ± 0.76
Minute volume (ml/min) 3.28 ± 0.25
Frequency (breaths/min) 238.0 + 6.63
Total cycle time (ms) 254.2 ± 7.32
Inspiration time (ms) 72.51 ± 3.85
Expiration time (ms) 137.7 ± 22.11
Inspiratory flow rate (μl/sec) 191.6 ± 12.93
Inspiratory duty cycle (%) 28.73 ± 1.66
Tidal volume (μl)/bw (g) 3.11 ± 0.11
Minute volume (ml/min)/bw (g) 744.0 ± 42.11
*p < 0.05, **p < 0.01, ***p <0.001.
Plethysmographic analysis of respiratory parameters in neonates exposed to normo
significant perturbation of lung function at P7, compared to normoxia controls, n =
Bw – body weight.difference in growth between the Hyp + PBS and Hyp +
CSF-1 groups (Figure 2A). From P11 at the end of treat-
ment (5.07 ± 0.13 g vs. 5.05 ± 0.16 g) to adulthood at P35
(17.70 ± 0.76 g vs. 17.35 ± 0.70 g), CSF-1 treatment did not
rescue body weight when compared to mice exposed to
hyperoxia and administered PBS (Figure 2A).
Removal of mice from hyperoxia resulted in a marked
improvement in lung structure. At the end of treatment
at P11, there was no significant difference in MLI, per-
centage tissue or percentage airspace amongst any of the
three groups (Table 2). However, there was a trend to-
wards increased MLI in the Hyp + PBS group compared
to Norm, and this increase was not observed in the CSF-1
treated group. In adulthood at P35, no significant differ-
ences were observed in any of the lung structure param-
eters investigated in any group. However, of note is that
all Hyp + CSF-1 values were more similar to Norm
values than Hyp + PBS, indicating that structural abnor-
malities had not been exacerbated with CSF-1 treatment.
A time course analysis of lung function was performed
from the conclusion of hyperoxia exposure at P7, at the
end of treatment at P11, and weekly throughout devel-
opment from P14 to adulthood at P35 (Figure 3). Tidal
volume (Figure 3A), minute volume (Figure 3B), tidal
volume/body weight ratio (Figure 3G) and inspiratory
flow rate (Figure 3I) all increased during postnatal devel-
opment, with all three groups following a similar trajec-
tory. No significant differences were observed at any time
point, with the exception of P21 when a significant reduc-
tion in tidal volume (79.5 ± 6.0 μl vs. 53.0 ± 5.0 μl, p < 0.01;
Figure 3A), minute volume (23.2 ± 1.3 ml vs. 15.9 ± 0.8 ml,
p < 0.05; Figure 3B) and tidal volume/body weight (7.4 ±
0.6 μl/g vs. 6.3 ± 0.4 μl/g, p < 0.05; Figure 3G) was ob-
served in the Hyp + CSF-1 group compared to Norm.
Some early alterations were observed in parameterson
Hyperoxia Significance p value
10.74 ± 0.34 *** 0.0008
2.34 ± 0.13 ** 0.0014
216.4 ± 6.18 * 0.031
276.9 ± 7.07 * 0.044
82.75 ± 3.64 0.076
206.4 ± 10.76 ** 0.005
133.5 ± 8.06 *** 0.0006
29.99 ± 1.29 0.55
2.98 ± 0.17 0.56
650.8 ± 48.17 0.19
xia or hyperoxia for 7 days following birth. Hyperoxia exposure resulted in
9/16 per group. Data were analysed using two-tailed unpaired t-tests.
Figure 2 Growth and macrophage analysis of mice treated with CSF-1 following hyperoxia. Body weights of mice treated with CSF-1
(Hyp + CSF-1; purple line) or PBS (Hyp + PBS; blue line) following hyperoxia exposure was significantly decreased compared to normoxic mice
(Norm; red line) (A). n = 4-13 mice/time point. Data were analysed using one-way ANOVAs and Tukey’s post-hoc tests. ‘a’ represents significant
difference between Norm and Hyp + PBS, ‘b’ represents significant difference between Norm and Hyp + CSF-1. Flow cytometric analysis of littermate
lungs at P11 treated with CSF-1 or PBS controls following hyperoxia (B-H). Total lung cells (B) were gated on csf1r-EGFP+ CD45+ cells to quantitate
CSF-1R+ cell number and proportion (C) after CSF-1 (D) and PBS treatment (E). F4/80 expression demarcates mature macrophages within the CSF-1R+
population (F-H). Histograms revealing gating procedure for F4/80 expression in representative PBS (G) and CSF-1-treated lungs (H). Staining (blue) is
overlayed with an isotype control (red). CSF-1 treatment resulted in a significant increase in total cellularity, CSF-1R+ cell number and macrophage
number. n = 4 littermate lungs/treatment. Data were analysed using two-tailed unpaired t-tests. *p < 0.05, ***p < 0.001.
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inspiration time (Figure 3E) and minute volume/body
weight (Figure 3H), where at P11 CSF-1-treated mice had
significant alterations in breathing patterns compared to
Norm or Hyp + PBS mice. Furthermore, only in frequency
(Figure 3C), expiration time (Figure 3F) and minute vol-
ume/body weight (Figure 3H) was there an alteration with
CSF-1 treatment that was significantly different comparedto PBS administration at P11. However, any earlier pertur-
bations associated with hyperoxia exposure and/or CSF-1
administration resolved and at P35 no significant differ-
ence was observed amongst the three treatment groups in
the breathing parameters examined.
To investigate the impact of CSF-1 treatment on lung
macrophages, flow cytometry was performed on litter-
mate hyperoxic lungs after treatment with either PBS or
Table 2 Morphometric analysis of lungs from
CSF-1-treated mice after 7 days of neonatal hyperoxia
exposure
Normoxia Hyp + PBS Hyp + CSF-1
P11 % Tissue 50.66 ± 1.61 53.62 ± 2.99 52.98 ± 1.90
% Airspace 49.34 ± 1.61 46.38 ± 2.99 47.02 ± 1.90
MLI 88.59 ± 2.42 94.33 ± 2.37 87.42 ± 0.99
P35 % Tissue 36.97 ± 1.29 39.15 ± 2.01 35.92 ± 0.87
% Airspace 63.03 ± 1.29 60.85 ± 2.01 64.08 ± 0.87
MLI 64.99 ± 1.78 68.67 ± 1.64 67.34 ± 1.63
Morphometric estimation of percentage tissue, percentage airspace and mean
linear intercept (MLI) at P11 (n = 4 lungs/treatment) and P35 (n = 6-7
lungs/treatment) in newborn mice exposed to normoxia or hyperoxia for
7 days followed by either CSF-1 or PBS treatment for 5 consecutive days. No
significant changes were observed in the morphometric parameters examined
amongst the three treatment groups. Data were analysed using one-way
ANOVAs and Tukey’s post-hoc tests.
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significantly increased by 13% in mice treated with CSF-1
(128 ± 5.3 × 105 vs. 144 ± 3.1 × 105, p < 0.05; Figure 2B).
Transgenic csf1r-EGFP mice, which express EGFP under
control of the csf1r promoter, identified CSF-1-responsive
cells. The number of CSF-1R+ cells significantly increased
by 34% with CSF-1 treatment compared to PBS (16.7 ±
0.2 × 104 vs. 22.2 ± 2.2 × 104, p < 0.05; Figure 2C). CSF-1R
was not expressed outside the leukocyte population, with
no CD45- lung cells found to express the EGFP transgene
(Figure 2D&E). F4/80 expression was used to identify ma-
ture macrophages (Figure 2F-H). The number of F4/80+
macrophages significantly increased by 34% with CSF-1
treatment at P11 (88 ± 2.0 × 103 vs. 118 ± 9.0 × 103, p < 0.05;
Figure 2F).
Delivery of CSF-1 in conjunction with hyperoxia exposure
resulted in reduced body weight; however structural
alterations were not exacerbated and pulmonary
macrophages were not increased
In the second treatment regime, CSF-1 was administered
in conjunction with high oxygen exposure to assess the
potential of CSF-1 to mitigate lung damage and promote
alveolar formation. In this more clinically relevant re-
gime, neonatal mice were exposed to hyperoxia for
5 days to allow for 5 concurrent daily injections of CSF-
1 or PBS. Body weight was measured to assess growth
over the time course of development, from the end of
treatment at P5, and weekly throughout postnatal devel-
opment from P14 to adulthood at P35 (Figure 4A). Body
weight was not significantly altered in the Hyp + PBS
group compared to Norm. These two treatment groups
followed a similar growth trajectory and no significant
changes were observed at any of the time points examined.
However, Hyp +CSF-1 was found to negatively affect body
weight, although this emerged only at later time points. By
P28, the growth trajectory was decreased in the Hyp +CSF-1 group and body weight was significantly lower than
in the Norm group (17.27 ± 0.54 g vs. 15.20 ± 0.42 g,
p < 0.001). Also, at P35, body weight was significantly lower
in the Hyp + CSF-1 group compared to both the Norm
(21.47 ± 0.51 g vs. 18.50 ± 0.53 g, p < 0.001) and Hyp +
PBS groups (20.89 ± 0.61 g vs. 18.50 ± 0.53 g, p < 0.001;
Figure 4A).
The effect of hyperoxia and concurrent CSF-1 treat-
ment on structural development of the lung was
assessed at P5 (Table 3). No significant differences were
observed in the structural parameters examined between
the three groups. A trend of altered structural measure-
ments was observed in the Hyp + PBS group compared to
Norm, although it did not reach significance. In the Hyp +
CSF-1 group, all parameters measured approached the
values of the Norm group and structural alterations were
not exacerbated with CSF-1 administration. In the adult at
P35, percentage tissue and airspace were unaltered in the
Hyp + PBS or Hyp +CSF-1 groups compared to Norm.
However, MLI was affected by hyperoxia exposure. Com-
pared to Norm, a significant increase in MLI was observed
in the Hyp + PBS (65.0 ± 1.8 μm vs. 72.7 ± 1.2 μm, p < 0.05)
and the Hyp + CSF-1 groups (65.0 ± 1.8 μm vs. 75.3 ±
2.8 μm, p < 0.01; Table 3). CSF-1 treatment did not signifi-
cantly affect the outcome of hyperoxia on the lung, as no
significant difference in MLI compared to PBS was ob-
served. Histologically, there were fewer and larger alveoli
in the lungs of mice exposed to both Hyp + PBS (Figure 4J)
and Hyp + CSF-1 (Figure 4K) as compared to Norm con-
trols (Figure 4I).
Plethysmographic analysis of breath parameters (Figure 5)
indicated that initial perturbations at P5 were present in
breath frequency (Figure 5C), total cycle time (Figure 5D),
inspiration time (Figure 5E), expiration time (Figure 5F)
and minute volume/body weight ratio (Figure 5H). How-
ever, these alterations were observed in both hyperoxia
groups compared to Norm, and were thus not a result of
CSF-1 delivery. After initial perturbation at P5, breathing
frequency, total cycle time and expiration time were subse-
quently comparable amongst all treatment groups. Inspir-
ation time was altered in the hyperoxia groups compared
to Norm, with a significant decrease at P21 (Norm vs.
Hyp + PBS 15%, p < 0.05; Norm vs. Hyp + CSF-1 23%, p <
0.01) and P28 (Norm vs. Hyp + PBS 17%, p < 0.01; Norm
vs. Hyp +CSF-1 16%, p < 0.05; Figure 5E). Tidal volume
(Figure 5A), minute volume (Figure 5B) and inspiratory
flow rate (Figure 5I) increased during postnatal life and
followed a similar trajectory in all three treatment groups.
No significant differences were observed in inspiratory flow
rate at any time points. However, at P35 in the Hyp +
CSF-1 group there was a significant decrease in tidal vol-
ume (122.84 ± 5.98 μl vs. 98.36 ± 4.26 μl, p < 0.001;
Figure 5A) and minute volume (38.7 ± 2.1 ml vs. 32.0 ±
1.9 ml, p < 0.01; Figure 5B) compared to Norm.
Figure 3 Lung function of mice treated with CSF-1 following hyperoxia exposure. Plethysmography assessment of lung function parameters
- tidal volume (A), minute volume (B), frequency (C), total cycle time (D), inspiration time (E), expiration time (F), tidal volume/bodyweight (G), minute
volume/bodyweight (H), inspiratory flow rate (I) - in mice treated with CSF-1 (Hyp + CSF-1; purple line) or PBS (Hyp + PBS; blue line) following hyper-
oxia exposure, compared to normoxic controls (Norm; red line). n = 6-14 mice/treatment/time point. Data were analysed using two-way ANOVAs and
Bonferonni post-hoc tests. ‘a’ represents significant difference between Norm and Hyp + PBS, ‘b’ represents significant difference between Norm and
Hyp + CSF-1, ‘c’ represents significant difference between Hyp + PBS and Hyp + CSF-1. *p < 0.05, **p < 0.01, ***p < 0.001.
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macrophages, flow cytometry was performed on littermate
lungs at P5, after either PBS or CSF-1 treatment was deliv-
ered concurrently with hyperoxia. Total lung cell number
was not altered with CSF-1 treatment, with no significant
change compared to PBS was observed (Figure 4B). Csf1r-
EGFP transgene expression on CD45+ leukocytes revealed
that the number and percentage of CSF-1R+ cells within
the lung was comparable amongst both PBS and CSF-1-
treated mice (Figure 4C-E). Similarly, when cells were fur-
ther gated on F4/80 expression to identify macrophages
(Figure 4G&H), no change in the number or percentage
of macrophages in the lung was observed as a result of
CSF-1 treatment (Figure 4F).Discussion
Oxygen supplementation remains a critical and lifesaving
intervention for infants with respiratory distress; however,
it can result in detrimental alterations to the developing
lung. Exposing neonatal mice to high concentrations of
oxygen mimics the damage to the lung associated with
BPD, providing a relevant model to assess the function of
CSF-1 in rescuing and enhancing alveolar formation. This
study employed a hyperoxia regime of 65% oxygen for
1 week after birth, providing a milder, more clinically-
relevant exposure that more closely resembles the oxygen
therapy regime of ventilated premature infants than other
previous studies [5,35]. It was also selected to minimize ma-
ternal oxygen toxicity and avoid stress and abandonment
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Growth and macrophage analysis in mice treated with CSF-1 during concurrent hyperoxia exposure. Body weights of mice
treated with CSF-1 (Hyp + CSF-1; purple line) or PBS (Hyp + PBS; blue line) during hyperoxia exposure compared to normoxic mice (Norm; red line)
(A). n = 4-13 mice/time point. Data were analysed using a two-way ANOVA and Bonferonni post-hoc test. ‘b’ represents significant difference between
Norm and Hyp + CSF-1, ‘c’ represents significant difference between Hyp + PBS and Hyp + CSF-1. ***p < 0.001. Flow cytometric analysis of littermate lungs
at P5 following treatment with CSF-1 or PBS during hyperoxia. Total lung cells (B) were gated on csf1r-EGFP+ CD45+ cells to quantitate CSF-1R+ cell
number and proportion (C) after CSF-1 (E) and PBS treatment (D). F4/80 expression demarcates mature macrophages within the CSF-1R+ population
(F-H). Histograms revealing gating procedure for F4/80 expression in representative PBS (G) and CSF-1-treated lungs (H). Staining (blue) is overlayed with
an isotype control (red). n = 3 littermate lungs/treatment. Data were analysed using two-tailed unpaired t-tests. Photomicrographs of Norm (I), Hyp + PBS
(J) and Hyp + CSF-1 (K) lungs at P35 stained with H&E demonstrated fewer, larger alveoli with hyperoxia exposure (J & K).
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hyperoxia model included growth restriction, impaired lung
structural development indicative of reduced alveolarisa-
tion, and as a consequence measurable perturbations of re-
spiratory function. While body weight was comparable at
birth, hyperoxia impacted negatively on neonatal growth as
evidenced by the reduction in body weight in the hyperoxia
group by the end of exposure. Although there is potential
for maternal oxygen toxicity to impact on the growth re-
striction observed, such growth restriction associated with
this model is important to examine the growth promoting
functions of CSF-1 as observed previously [23]. Lung struc-
tural alterations characteristic of oxygen toxicity and BPD
were also observed. MLI and percentage airspace were in-
creased, while percentage tissue was decreased. This is in
agreement with other hyperoxia studies, where oxygen sup-
plementation caused BPD-like pathological changes to the
lung parenchyma and impaired alveolarisation resulting in
fewer, larger alveoli [5,6].
Functional perturbations were also revealed following
hyperoxia. Unrestrained barometric whole-body plethys-
mography proved a beneficial analytical technique sensi-
tive enough to reveal measurable differences in neonates
at 7 days of age. While the accuracy of absolute quanti-
tation in small animals is debatable [36], this technique
provides a qualitative comparative assessment applicable
to this study. Furthermore, the non-invasive nature of
this technique makes it invaluable for these experimentsTable 3 Morphometric analysis of lungs from mice
administered CSF-1 during concurrent hyperoxia exposure
Normoxia Hyp + PBS Hyp + CSF-1
P5 % Tissue 34.92 ± 1.83 28.31 ± 1.83 32.15 ± 1.74
% Airspace 65.08 ± 1.83 71.69 ± 1.83 67.85 ± 1.74
MLI 113.00 ± 3.22 121.70 ± 7.97 116.40 ± 3.45
P35 % Tissue 36.97 ± 1.29 38.48 ± 2.01 36.92 ± 0.88
% Airspace 63.03 ± 1.29 61.52 ± 2.01 63.08 ± 0.88
MLI 64.99 ± 1.78 72.66 ± 1.22 a* 75.27 ± 2.79 b**
Morphometric estimation of percentage tissue, percentage airspace and mean
linear intercept at P5 at the cessation of treatment (n = 4-5/group), and at P35
(n = 6-7/group). Data were analysed by one-way ANOVA and Tukey’s post-hoc test.
‘a’ represents significant difference between Norm and Hyp + PBS, ‘b’ represents
significant difference between Norm and Hyp + CSF-1. *p < 0.05, **p < 0.01.in assessing the effects of CSF-1 and the rescue of lung
function over time. Abnormal breathing patterns were
associated with hyperoxia exposure after 7 days. In
agreement with previously reported effects of hyperoxia
on pulmonary activity [37], changes included an increase
in total cycle time primarily due to lengthened expiratory
time. Furthermore, hyperoxia resulted in a reduction in
tidal volume, supporting the structural observation of im-
paired alveolar formation. However, effects on tidal and
minute volumes were mitigated when normalised to body
weight, suggesting that the overall growth restriction con-
tributes to the reduced lung volumes.
Harnessing the organogenic importance of growth fac-
tors involved in alveolar formation has been a fundamen-
tal strategy for promoting lung maturation. Factors such
as keratinocyte growth factor [38], hepatocyte growth fac-
tor [39], retinoic acid [40] and vascular endothelial growth
factor [41] are important in alveolarisation and have
shown positive effects in rescuing alveolar development in
hyperoxic animal studies. The injury-induced perturbation
of development associated with BPD is also being tackled
by using anti-inflammatory approaches, such as interleu-
kin (IL)-10 [42] or inflammatory chemokine blockade
[43], and by optimising ventilation strategies [44] to miti-
gate damage and protect alveolar formation.
CSF-1 provides a particularly attractive candidate for use
in this setting because it is a growth factor with proven
organogenic [27,28], anti-inflammatory [29,45] and regen-
erative capabilities [12,46]. During development, endogen-
ous CSF-1 preferentially regulates trophic macrophages
associated with organogenesis, as evidenced by the wide-
spread developmental defects observed in CSF-1-deficient
mice [20-22]. Functions of trophic macrophages that sup-
port organogenesis include apoptotic clearance of cellular
debris associated with tissue remodelling [47], regulation of
angiogenesis through the production of angiogenic factors
[48,49] and by physically directing vascular development
[50]. Macrophages act as potent effector cells producing a
range of important trophic mediators such as insulin-like
growth factor-1 (IGF-1) [51], wingless-type MMTV inte-
gration site family, member 7b (Wnt7b) [52], transforming
growth factor-β (TGF-β) [53] and MMP9 [54], which are
involved in epithelial proliferation and matrix reorganisa-
tion. These processes are all essential in lung development,
Figure 5 Lung function of mice treated with CSF-1 during concurrent hyperoxia exposure. Plethysmographic assessment of lung function
parameters - tidal volume (A), minute volume (B), frequency (C), total cycle time (D), inspiration time (E), expiration time (F), tidal volume/body-
weight (G), minute volume/bodyweight (H), inspiratory flow rate (I) - in mice treated with CSF-1 (Hyp + CSF-1; purple line) or PBS (Hyp + PBS; blue
line) during hyperoxia exposure compared to normoxia (Norm; red line). n = 6-14 mice/treatment/time point. Data were analysed using
two-way ANOVAs and Bonferonni post-hoc tests. ‘a’ represents significant difference between Norm and Hyp + PBS, ‘b’ represents significant
difference between Norm and Hyp + CSF-1. *p < 0.05, **p < 0.01, ***p < 0.001.
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embryonic lung and the postnatal lung undergoing alveo-
larisation demonstrate a gene expression profile, indicative
of a trophic M2 macrophage activation state [23,27].
The role of CSF-1 in polarising macrophages towards
an M2 phenotype may also provide beneficial effects in
hyperoxia through its involvement in immune dampening
[29]. Inflammation has a negative impact on lung develop-
ment [55,56]. Inflammatory cell influx and release of pro-
inflammatory mediators promotes apoptotic and necrotic
cell death that disrupts lung morphogenesis and impairs
function. Furthermore, inflammatory activation disrupts
organogenic signalling pathways by altering expression ofkey genes important in lung development [57,58]. While
inflammatory challenges such as lipopolysaccharide (LPS)
or IL-1β administration in animal models of chorioam-
nionitis promote lung maturation, the mechanism is
distinct from alveolarisation and is instead a survival
adaptation that comes at the expense of proper alveolar
formation resulting in a lung pathology associated with
BPD [59].
The infiltration of inflammatory macrophages is asso-
ciated with the progression of lung injury and pathology
[60,61]. However macrophage diversity is revealing the
importance of lung macrophages in both the injury and
repair stages [16], and differential activation suggests
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may be distinct from CSF-1-mediated stimulation of
macrophages to take on a remodelling/anti-inflamma-
tory M2 phenotype [29]. In a recent study, CSF-1 was
associated with repair and rescue of alveolar formation
following hyperoxia in the mouse [30]. It was reported
that the administration of MSC–conditioned media
into a neonatal murine hyperoxia model reduced in-
flammation and prevented alveolar and vascular dam-
age [30]. Interestingly, this correlated with high levels of
CSF-1, indicating that the developmentally protective ef-
fect of MSCs may be indirectly mediated by the immuno-
modulatory effect of CSF-1 [30].
In the present study, CSF-1 was administered to a neo-
natal murine hyperoxia model and growth, lung structure
and respiratory function were assessed. In the first treat-
ment regime, CSF-1 was administered post-hyperoxic
injury to investigate whether CSF-1 could rescue develop-
mental perturbation and promote alveolar formation.
Results demonstrated limited success of CSF-1 in the miti-
gation of hyperoxia-induced injury. Deficits in growth were
not improved, with the body weights of CSF-1-treated
mice comparable to the Hyp + PBS group. With regard to
lung function, a negative impact was revealed at P11 at the
end of treatment. In parameters such as total cycle time,
expiration time and minute volume/body weight ratio the
detrimental effect of hyperoxia was exacerbated with CSF-
1. Interestingly, these initial defects did normalise over
time and by P35 no differences between treatment groups
were observed. This normalisation was also seen in the
Hyp + PBS group, and therefore CSF-1 treatment did not
accelerate or enhance functional recovery, although in-
creased numbers of CSF-1R+ macrophages were evident.
Nevertheless, it is noteworthy that CSF-1 did not have a
negative impact on the parameters measured in the adult.
It is interesting that earlier perturbations observed with
hyperoxia resolved by adulthood. Whether this impacts
on the lungs capacity to cope with challenges and aging in
later life is unknown. Furthermore questions remain about
potential negative effects associated with catch up growth.
Indeed CSF-1R+ macrophages have been shown to be in-
creased in the alveolarisation stage of lung development
[23], however whether in this setting the increase in CSF-
1R+/F4/80+ macrophages is retained and whether it is as-
sociated with positive or negative outcomes in lung
physiology is also of ongoing interest.
Oxygen supplementation is a critical life saving inter-
vention for babies with respiratory distress, and clinically
any maturation-based therapies would need to be deliv-
ered concurrently. Therefore, in the second part of this
study, CSF-1 was administered from birth in conjunc-
tion with hyperoxic exposure, in a setting where a prophy-
lactic effect of CSF-1 treatment was aimed at preventing
damage and alveolar loss and enhancing alveolarisation. Ashortened exposure time was utilised to enable the 5 daily
doses to be administered in conjunction with hyperoxia.
The lack of growth restriction is likely due to the de-
creased oxygen exposure, as pup litters size was consistent
amongst regimes. Structurally and functionally, the lungs
of both hyperoxia groups were impacted negatively. Mor-
phometric analysis in the adult revealed significant in-
creases in MLI, with fewer, larger alveoli in both the Hyp +
PBS and Hyp +CSF-1 groups compared to Norm. Al-
though CSF-1 was not found to improve the structural al-
terations caused by hyperoxia, this treatment did not
exacerbate the negative impact of hyperoxia and no signifi-
cant difference between PBS and CSF-1-treated mice was
observed. There were no differences between any groups at
P5, although this time coincides with the beginning of the
alveolarisation phase. Of note is that Hyp +CSF-1 values
began to approach Norm values in all parameters. Func-
tionally in the adult, CSF-1 did not exacerbate the adverse
effects on lung function that were characteristic of hyper-
oxia exposure, as represented by the Hyp + PBS group.
Although no negative effect of CSF-1 was identified, it
must be noted that no functionally beneficial effects
with regard to preventing hyperoxic damage or further
enhancing lung development were observed. The only
changes with CSF-1 at P35 were in tidal volume and mi-
nute volume. However, these were normalised when
body weight was accounted for and, relative to their
size, there were no changes in these parameters as a re-
sult of CSF-1 treatment.
Overall, CSF-1 treatment showed little effect in pro-
moting alveolar formation in the hyperoxic settings
employed in this study. Ongoing studies examining the
role of M2 polarisation in the protection and rescue of
hyperoxic injury with be important before a definitive
statement that CSF-1-responsive macrophages are not
effective can be made. Also further experiments utilizing
a premature birth model – where animals are prema-
turely removed from their high uterine CSF-1 environ-
ment – will be important to better model this aspect of
the clinical situation. However, in this study the finding
that CSF-1 treatment did not exacerbate the pathological
response to high oxygen levels was encouraging in that
macrophage-mediation may provide a novel strategy for
the immunomodulation and trophic promotion of alveolar
development. In particular in the second regime where po-
tential negative outcomes were a legitimate concern, CSF-1
did not exacerbate damage with concurrent oxygen supple-
mentation. This is a significant finding that is important for
any potential clinical use of CSF-1, and supports ongoing
studies to improve understanding of the role of CSF-1 in al-
veolar formation.Competing interests
CVJ and SDR hold patents relating to CSF-1 and organ growth.
Jones et al. Respiratory Research 2014, 15:110 Page 13 of 14
http://respiratory-research.com/content/15/1/110Authors’ contributions
CVJ contributed to study design, performed the experiments and analysis of
data, and wrote the manuscript. MAA assisted with plethysmography, TMW
performed flow cytometry, MoR and FS assisted with the hyperoxia model,
equipment and provided critical drafting of the manuscript under the direction
of RH, GJ provided intellectual input and critical drafting of the manuscript, and
SDR oversaw study design and coordination, data interpretation and writing of
the manuscript. All authors read and approved the final manuscript.
Author details
1Department of Anatomy and Developmental Biology, Monash University,
Clayton, Victoria, Australia. 2The Ritchie Centre, Monash Institute of Medical
Research and Department of Obstetrics Gynaecology, Monash University,
Clayton, Victoria, Australia.
Received: 7 March 2014 Accepted: 28 August 2014
Published: 6 September 2014References
1. Gien J, Kinsella JP: Pathogenesis and treatment of bronchopulmonary dysplasia.
Curr Opin Pediatr 2011, 23:305–313. 310.1097/MOP.1090b1013e328346577f.
2. Kinsella JP, Greenough A, Abman SH: Bronchopulmonary dysplasia.
Lancet 2006, 367:1421–1431.
3. Jobe AJ: The new BPD: an arrest of lung development. Pediatr Res 1999,
46:641–643.
4. Merritt TA, Deming DD, Boynton BR: The ‘new’ bronchopulmonary
dysplasia: challenges and commentary. Semin Fetal Neonat M 2009,
14:345–357.
5. Warner BB, Stuart LA, Papes RA, Wispe JR: Functional and pathological effects
of prolonged hyperoxia in neonatal mice. Am J Physiol 1998, 275:L110–L117.
6. Dauger S, Ferkdadji L, Saumon G, Vardon G, Peuchmaur M, Gaultier C, Gallego J:
Neonatal exposure to 65% oxygen durably impairs lung architecture and
breathing pattern in adult mice. Chest 2003, 123:530–538.
7. Burri PH: Structural aspects of postnatal lung development - alveolar
formation and growth. Biol Neonate 2006, 89:313–322.
8. Schittny JC, Burri H: Development and Growth of the Lung. In Fishman’s
Pulmonary Diseases and Disorders. 4th edition. Edited by Fishman AP.
New York: The McGraw Hill Companies, Inc; 2008:91–114.
9. Coalson JJ: Pathology of new bronchopulmonary dysplasia.
Semin Neonatol 2003, 8:73–81.
10. Bourbon J, Boucherat O, Chailley-Heu B, Delacourt C: Control mechanisms
of lung alveolar development and their disorders in bronchopulmonary
dysplasia. Pediatr Res 2005, 57:38R–46R.
11. Bhandari V: Hyperoxia-derived lung damage in preterm infants.
Semin Fetal Neonatal Med 2010, 15:223–229.
12. Alikhan MA, Jones CV, Williams TM, Beckhouse AG, Fletcher AL, Kett MM,
Sakkal S, Samuel CS, Ramsay RG, Deane JA, Wells CA, Little MH, Hume DA,
Ricardo SD: Colony-stimulating factor-1 promotes kidney growth and
repair via alteration of macrophage responses. Am J Pathol 2011,
179:1243–1256.
13. Stefater JA 3rd, Ren S, Lang RA, Duffield JS: Metchnikoff’s policemen:
macrophages in development, homeostasis and regeneration.
Trends Mol Med 2011, 7:743–752.
14. Pollard JW: Trophic macrophages in development and disease.
Nat Rev Immunol 2009, 9:259–270.
15. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage
activation. Nat Rev Immunol 2008, 8:958–969.
16. Johnston LK, Rims CR, Gill SE, McGuire JK, Manicone AM: Pulmonary
macrophage subpopulations in the induction and resolution of acute
lung injury. Am J Respir Cell Mol Biol 2012, 47:417–426.
17. Pixley FJ, Stanley ER: CSF-1 regulation of the wandering macrophage:
complexity in action. Trends Cell Biol 2004, 14:628–638.
18. Bartocci A, Pollard JW, Stanley ER: Regulation of colony-stimulating factor
1 during pregnancy. J Exp Med 1986, 164:956–961.
19. Ovchinnikov DA: Macrophages in the embryo and beyond: much more
than just giant phagocytes. Genesis 2008, 46:447–462.
20. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, Ahmed-Ansari A, Sell KW,
Pollard JW, Stanley ER: Total absence of colony-stimulating factor 1 in the
macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U
S A 1990, 87:4828–4832.21. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo
T, Shultz LD, Nishikawa S: The murine mutation osteopetrosis is in the
coding region of the macrophage colony stimulating factor gene.
Nature 1990, 345:442–444.
22. Pollard JW, Stanley ER: Pleiotropic roles for CSF-1 in development defined by
the mouse mutant osteopetrotic (op). Adv Dev Biochem 1996, 4:153–193.
23. Jones CV, Williams TM, Walker KA, Dickinson H, Sakkal S, Rumballe BA, Little MH,
Jenkin G, Ricardo SD: M2 macrophage polarisation is associated with alveolar
formation during postnatal lung development. Respir Res 2013, 14:41.
24. Wiktor-Jedrzejczak W, Ratajczak MZ, Ptasznik A, Sell KW, Ahmed-Ansari A,
Ostertag W: CSF-1 deficiency in the op/op mouse has differential effects
on macrophage populations and differentiation stages.
Exp Hematol 1992, 20:1004–1010.
25. Roth P, Dominguez MG, Stanley ER: The effects of colony-stimulating
factor-1 on the distribution of mononuclear phagocytes in the
developing osteopetrotic mouse. Blood 1998, 91:3773–3783.
26. Shibata Y, Zsengeller Z, Otake K, Palaniyar N, Trapnell BC: Alveolar macrophage
deficiency in osteopetrotic mice deficient in macrophage colony-stimulating
factor is spontaneously corrected with age and associated with matrix
metalloproteinase expression and emphysema. Blood 2001, 98:2845–2852.
27. Rae F, Woods K, Sasmono T, Campanale N, Taylor D, Ovchinnikov DA,
Grimmond SM, Hume DA, Ricardo SD, Little MH: Characterisation and
trophic functions of murine embryonic macrophages based upon the
use of a Csf1r-EGFP transgene reporter. Dev Biol 2007, 308:232–246.
28. Geutskens SB, Otonkoski T, Pulkkinen MA, Drexhage HA, Leenen PJ:
Macrophages in the murine pancreas and their involvement in fetal
endocrine development in vitro. J Leukoc Biol 2005, 78:845–852.
29. Hamilton JA: Colony-stimulating factors in inflammation and
autoimmunity. Nat Rev Immunol 2008, 8:533–544.
30. Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA,
Kourembanas S: Bone marrow stromal cells attenuate lung injury in a
murine model of neonatal chronic lung disease. Am J Respir Crit Care Med
2009, 180:1122–1130.
31. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright BJ, Ostrowski
MC, Himes SR, Hume DA: A macrophage colony-stimulating factor receptor-
green fluorescent protein transgene is expressed throughout the
mononuclear phagocyte system of the mouse. Blood 2003, 101:1155–1163.
32. Milton PL, Dickinson H, Jenkin G, Lim R: Assessment of respiratory
physiology of C57BL/6 mice following bleomycin administration using
barometric plethysmography. Respiration 2012, 83:253–266.
33. Murphy S, Lim R, Dickinson H, Acharya R, Rosli S, Jenkin G, Wallace E:
Human amnion epithelial cells prevent bleomycin-induced lung injury
and preserve lung function. Cell Transplant 2011, 20:909–923.
34. Dunnill MS: Quantitative methods in the study of pulmonary pathology.
Thorax 1962, 17:320–328.
35. Rogers LK, Valentine CJ, Pennell M, Velten M, Britt RD, Dingess K, Zhao X,
Welty SE, Tipple TE: Maternal docosahexaenoic acid supplementation
decreases lung inflammation in hyperoxia-exposed newborn mice.
J Nutr 2011, 141:214–222.
36. Enhorning G, Sv S, Lundgren C, Vargas I: Whole-body plethysmography,
does it measure tidal volume of small animals? Can J Physiol Pharm 1998,
76:945–951.
37. Mortola JP, Tenney SM: Effects of hyperoxia on ventilatory and metabolic
rates of newborn mice. Respir Physiol 1986, 63:267–274.
38. Franco-Montoya ML, Bourbon JR, Durrmeyer X, Lorotte S, Jarreau PH, Delacourt
C: Pulmonary effects of keratinocyte growth factor in newborn rats
exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol 2009, 297:L965–L976.
39. Ohki Y, Mayuzumi H, Tokuyama K, Yoshizawa Y, Arakawa H, Mochizuki H,
Morikawa A: Hepatocyte growth factor treatment improves alveolarization
in a newborn murine model of bronchopulmonary dysplasia. Neonatology
2009, 95:332–338.
40. Zimova-Herknerova M, Myslivecek J, Potmesil P: Retinoic acid
attenuates the mild hyperoxic lung injury in newborn mice. Physiol Res
2008, 57:33–40.
41. Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Montgomery G,
Grover TR, Abman SH: Recombinant human VEGF treatment enhances
alveolarization after hyperoxic lung injury in neonatal rats.
Am J Physiol Lung Cell Mol Physiol 2005, 289:L529–L535.
42. Hoegl S, Boost KA, Czerwonka H, Dolfen A, Scheiermann P, Muhl H, Zwissler
B, Hofstetter C: Inhaled IL-10 reduces biotrauma and mortality in a model
of ventilator-induced lung injury. Respir Med 2009, 103:463–470.
Jones et al. Respiratory Research 2014, 15:110 Page 14 of 14
http://respiratory-research.com/content/15/1/11043. Liao L, Ning Q, Li Y, Wang W, Wang A, Wei W, Liu X, Auten RL, Tanswell AK,
Luo X: CXCR2 blockade reduces radical formation in hyperoxia-exposed
newborn rat lung. Pediatr Res 2006, 60:299–303.
44. Ramanathan R, Sardesai S: Lung protective ventilatory strategies in very
low birth weight infants. J Perinatol 2008, 28:S41–S46.
45. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD: Granulocyte-macrophage
colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage
phenotypes display differences in cytokine profiles and transcription factor
activities: implications for CSF blockade in inflammation. J Immunol 2007,
178:5245–5252.
46. Yano T, Miura T, Whittaker P, Miki T, Sakamoto J, Nakamura Y, Ichikawa Y, Ikeda
Y, Kobayashi H, Ohori K, Shimamono K: Macrophage colony-stimulating factor
treatment after myocardial infarction attenuates left ventricular dysfunction
by accelerating infarct repair. J Am Coll Cardiol 2006, 47:626–634.
47. Lang RA, Bishop JM: Macrophages are required for cell death and tissue
remodeling in the developing mouse eye. Cell 1993, 74:453–462.
48. Stefater JA 3rd, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J,
Ajima R, Molkentin JD, Williams BO, Wills-Karp M, Pollard JW, Yamaguchi T, Ferrara
N, Gerhardt H, Lang RA: Regulation of angiogenesis by a non-canonical Wnt-
Flt1 pathway in myeloid cells. Nature 2011, 474:511–515.
49. Nucera S, Biziato D, De Palma M: The interplay between macrophages
and angiogenesis in development, tissue injury and regeneration.
Int J Dev Biol 2011, 55:495–503.
50. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykholzhij S, Peri F, Wilson
SW, Ruhrberg C: Tissue macrophages act as cellular chaperones for
vascular anastomosis downstream of VEGF-mediated endothelial tip cell
induction. Blood 2010, 116:829–840.
51. Wynes MW, Riches DW: Induction of macrophage insulin-like growth
factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol 2003,
171:3550–3559.
52. Rajagopal J, Carroll TJ, Guseh JS, Bores SA, Blank LJ, Anderson WJ, Yu J,
Zhou Q, McMahon AP, Melton DA: Wnt7b stimulates embryonic lung
growth by coordinately increasing the replication of epithelium and
mesenchyme. Development 2008, 135:1625–1634.
53. Nacu N, Luzina IG, Highsmith K, Lockatell V, Pochetuhen K, Cooper ZA, Gillmeister
MP, Todd NW, Atamas SP:Macrophages produce TGF-beta-induced (beta-ig-
h3) following ingestion of apoptotic cells and regulate MMP14 levels and
collagen turnover in fibroblasts. J Immunol 2008, 180:5036–5044.
54. Gibbs DF, Warner RL, Weiss SJ, Johnson KJ, Varani J: Characterization of
matrix metalloproteinases produced by rat alveolar macrophages.
Am J Respir Cell Mol Biol 1999, 20:1136–1144.
55. Speer CP: Pulmonary inflammation and bronchopulmonary dysplasia.
J Perinatol 2006, 26:S57–S62.
56. Speer CP: Chorioamnionitis, postnatal factors and proinflammatory
response in the pathogenetic sequence of bronchopulmonary dysplasia.
Neonatology 2009, 95:353–361.
57. Blackwell TS, Hipps AN, Yamamoto Y, Han W, Barham WJ, Ostrowski MC,
Yull FE, Prince LS: NF-kappaB signaling in fetal lung macrophages
disrupts airway morphogenesis. J Immunol 2011, 187:2740–2747.
58. Benjamin JT, Carver BJ, Plosa EJ, Yamamoto Y, Miller JD, Liu JH, van der Meer R,
Blackwell TS, Prince LS: NF-kappaB activation limits airway branching
through inhibition of Sp1-mediated fibroblast growth factor-10 expression.
J Immunol 2010, 185:4896–4903.
59. Kramer BW, Kallapur S, Newnham J, Jobe AH: Prenatal inflammation and
lung development. Semin Fetal Neonatal Med 2009, 14:2–7.
60. Frank JA, Wray CM, McAuley DF, Schwendener R, Matthay MA: Alveolar
macrophages contribute to alveolar barrier dysfunction in ventilator-induced
lung injury. Am J Physiol Lung Cell Mol Physiol 2006, 291:L1191–L1198.
61. Laskin DL, Sunil VR, Gardner CR, Laskin JD: Macrophages and tissue injury: agents
of defense or destruction? Annu Rev Pharmacol Toxicol 2011, 51:267–288.
doi:10.1186/s12931-014-0110-5
Cite this article as: Jones et al.: The effect of CSF-1 administration on
lung maturation in a mouse model of neonatal hyperoxia exposure.
Respiratory Research 2014 15:110.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
